The effect of purmorphamine and sirolimus on osteogenic differentiation of human bone marrow-derived mesenchymal stem cells

Biomedicine and Pharmacotherapy

Volumn 67, Issue 1, 2013, Pages 31-38

  Faghihi, F ^a,b   Baghaban Eslaminejad, M ^a   Nekookar, A ^a   Najar, M ^a   Salekdeh, G H ^a  

^a ROYAN INSTITUTE FOR REPRODUCTIVE BIOMEDICINE   (Iran)

^b Science and Culture University ^*  (Iran)

Author keywords

Human mesenchymal stem cells; Osteogenic differentiation; Purmorphamine; Sirolimus; Small molecules

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN TYPE 1; MORPHINE DERIVATIVE; OSTEOCALCIN; PURMORPHAMINE; RAPAMYCIN; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE MINERALIZATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; STEM CELL EXPANSION; UPREGULATION;

ALKALINE PHOSPHATASE; ANIMALS; BONE MARROW CELLS; CELL DIFFERENTIATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; MORPHOLINES; OSTEOBLASTS; OSTEOGENESIS; PURINES; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; SIROLIMUS; TIME FACTORS;

EID: 84873248808     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.10.004     Document Type: Article

References (41)

1. Heary R.F., Schlenk R.P., Sacchieri T.A., Barone D. Persistent iliac crest donor site pain: independent outcome assessment. Neurosurgery 2002, 50:510-516.
2. Hou C.H., Yang R., Hou S.M. Hospital-based allogenic bonebank - 10-year experience. J Hosp Infect 2005, 59:41-45.
3. Yang Y.G., Sykes M. Xenotransplantation: current status and a perspective on the future. Nat Rev Immunol 2007, 7:519-531.
4. Friedenstein A.J. Detrimined and inducible osteogenic precursure cells. Hard Tissue Growth Repair Remineralization 1973, 11:169-185.
5. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas J.D. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
6. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., et al. Human bone marrow stromal cells suppress T lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
7. Rasmusson I., Le Blanc K., Sundberg B., Ringdén O. Mesenchymalstem cells stimulate antibody secretion in human B cells. Scand J Immunol 2007, 65:336-343.
8. Friedenstein A.J., Deriglasova U.F., Kulagina N.N., Panasuk A.F., Rudakowa S.F., Ruadkow I.A. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974, 2:83-92.
9. Davatchi F., Abdollahi B.S., Mohyeddin M., Shahram F., Nikbin B. Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. Int J Rheum Dis 2011, 14:211-215.
10. Orozco L., Soler R., Morera C., Alberca M., Sánchez A., García-Sancho J. Intervertebral disc repair by autologous mesenchymal bone marrow cells: a pilot study. Transplantation 2011, 92:822-828.
11. Zhao D., Cui D., Wang B., Tian F., Guo L., Yang L., et al. Treatment of early stage osteonecrosis of the femoral head with autologous implantation of bone marrow-derived and cultured mesenchymal stem cells. Bone 2012, 50:325-330.
12. Gentleman E., Swain R.J., Evans N.D., Boonrungsiman S., Jell G., Ball M.D. Comparative materials differences revealed in engineered bone as a function of cell-specifi c differentiation. Nat Mater 2009, 8:763-770.
13. Scutt A., Bertram P. Bone marrow cells are targets for the anabolic actions of prostaglandin E2 on bone: induction of a transition from nonadherent to adherent osteoblast precursors. J Bone Miner Res 1995, 10:474-487.
14. Diefenderfer D.L., Osyczka A.M., Reilly G.C., Leboy P.S. BMP responsiveness in human mesenchymal stem cells. Connect Tissue Res 2003, 44:305-311.
15. Knippenberg M., Helderb M.N., Zandieh Doulabia B., Klein-Nulend J.K. Osteogenesis versus chondrogenesis by BMP-2 and BMP-7 in adipose stem cells. Biochem Biophys Res Commun 2006, 342:902-908.
16. Spinella-Jaegle S., Rawadi G., Kawai S., Gallea S., Faucheu C., Mollat P., et al. Sonic hedgehog increases the commitment of pluripotent mesenchymal cells into the osteoblastic lineage and abolishes adipocytic differentiation. J Cell Sci 2001, 114:2085-2094.
17. James A.W., Leucht P., Levi B., Carre A.L., Xu Y., Helms J.A., et al. Sonic Hedgehog influences the balance of osteogenesis and adipogenesis in mouse adipose-derived stromal cells. Tissue Eng Part A 2010, 16:2605-2616.
18. Reymond J.L., Bluma L.C., Deursen R. Exploring the chemical space of known and unknown organic small molecules at www.gdb.unibe.ch. Chimia 2011, 65:863-867.
19. Dobson C.M. Chemical space and biology. Nature 2004, 432:824-828.
20. Spring D.R. Chemical genetics to chemical genomics: small molecules offer big insights. Chem Soc Rev 2011, 34:472-482.
21. Wu X., Ding S., Gray N.S., Schultz P.G. Small molecule with osteogenesis-inducing activity in multipotent mesenchymal progenitor cell. J Am Chem Soc 2002, 124:14520-14521.
22. Wu X., Walker J., Zhang J., Ding S., Schultz P.G. Purmorphamine induces osteogenesis by activation of the hedgehog signaling pathway. Chem Biol 2004, 11:1229-1238.
23. Oliveira F.S., Bellesini L.S., da Silva Herrero C.F., Beloti M.M., Rosa A. Hedgehog signaling and osteoblast gene expression are regulated by purmorphamine in human mesenchymal stem cells. J Cell Biochem 2012, 113:204-208.
24. Plaisant M., Fontaine C., Cousin W., Rochet N., Dani C., Peraldi P. Activation of Hedgehog signaling inhibits osteoblast differentiation of human mesenchymal stem cells. Stem Cells 2009, 27:703-713.
25. Guba M., Graeb C., Jauch K.W., Geissler E. Pro- and anti- cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 2004, 77:1777-1782.
26. Lee K.W., Yook J.Y., Son M.Y., Kim M.J., Koo D.B., Han Y.M., et al. Rapamycin promotes the osteobastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway. Stem Cells Dev 2010, 19:557-568.
27. Isomoto S., Mattori K., Ohgushi H., Nakajima H., Tanaka Y. Rapamycin as an inhibitor of osteogenic differentiation in bone marrow-derived mesenchymal stem cells. J Orthop Sci 2007, 12:83-88.
28. Singha U.K., Jiang Y., Yu S., Luo M., Lu Y., Zhang J., et al. Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells and primary mouse bone marrow stromal cells. J Cell Biochem 2008, 103:434-446.
29. Andrews P.D. Discovering small molecules to control stem cell fate. Future Med Chem 2011, 3:1539-1549.
30. Sanchez C.P., He Y.Z. Bone growth during rapamycin therapy in young rats. BMC Pediatr 2008, 13:3-9.
31. Ogawa T., Tokuda M., Tomizawa K., Matsui H., Konishi R. Osteoblastic differentiation is enhanced by rapamycin in rat osteoblast-like osteosarcoma (ROS 17/2.8) cells. Biochem Biophys Res Commun 1998, 249:226-230.
32. Beloti M.M., Bellesini L.S., Rosa A.L. Purmorphamine enhances ostegenic activity of human osteoblasts derived from bone marrow mesenchymal cells. Cell Biol Int 2005, 29:537-541.
33. Canalis E., Raisz L.G. Effect of epidermal growth factor on bone formation in vitro. Endocrinology 1979, 104:862-869.
34. Hoemann C.D., El-Gabalawy H., McKee M.D. In vitro osteogenesis assays: influence of the primary cell source on alkaline phosphatase activity and mineralization. Pathol Biol 2009, 57:318-323.
35. Bellows C.G., Aubin J.E., Heersche J.N. Initiation and progression of mineralization of bone nodules formed in vitro: the role of alkaline phosphatase and organic phosphate. Bone Miner 1991, 14:27-40.
36. Weinreb M., Shinar D., Rodan G.A. Different pattern of alkaline phosphatase, osteopontin, and osteocalcin expression in developing rat bone visualized by in situ hybridization. J Bone Miner Res 1990, 5:831-842.
37. Merry K., Dodds R., Littlewood A., Gowen M. Expression of Osteopontin mRNA by osteoclasts and osteoblasts in modelling adult human bone. J Cell Sci 1993, 104:1013-1020.
38. Choi S.T., Kim J.H., Kang E.J., Lee S.W., Park M.C., Park Y.B., et al. Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis. Rheumatology 2008, 47:1775-1779.
39. Chen J., Shapiro H.S., Sodek J. Development expression of bone sialoprotein mRNA in rat mineralized connective tissues. J Bone Miner Res 1992, 6:7987-7997.
40. Ikeda T., Shirasawa T., Esaki Y., Yoshiki S. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest 1993, 92:2814-2820.
41. Chang X., Hou Z.M., Yasuaki S., Tomoo T., Akira Y. Quantitative study of alkaline phosphatase and osteocalcin in the process of new bone. Hua Xi Kou Qiang Yi Xue Za Zhi 2005, 23:424-426.